Anna Perez-Bosque, PhD

Faculty of Pharmacy (University of Barcelona)
Departament de Fisiologia
Avgda Joan XXIII, s/n
Barcelona Spain 08028

Any personal financial relationships? No

I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.

If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 04/15/2015 by Anna Perez--Bosque

Papers:
F.4 Dietary plasma protein supplementation ameliorates intestinal inflammation in a mice model of double challenge inflammation
T.110 Dietary porcine plasma protein attenuates inflammatory severity in the mdr1a-/- mouse model of colitis.

	I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.
	The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.
	If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".